Drug Trial Radar · NCT07792954
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Mar 14, 2028
Study completion May 23, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions. The purpose of this study is to learn whether berobenatide is safe and effective for adults in China who have overweight or obesity. Researchers will compare berobenatide with a placebo, which looks like the study treatment but does not contain active medicine. People may be able to participate if they are adults with obesity or if they have overweight together with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment. Participants will be randomly assigned to receive either berobenatide or placebo. The study treatment will be administered according to the study protocol, and participants will be monitored throughout the study to assess changes in body weight and overall health, as well as any side effects that may occur. During participation, participants will attend study visits and complete study-related assessments. Researchers will collect information about participants' health, body weight, and safety throughout the study. Details about the number of visits, study duration, and study procedures will be explained by the study team before participation. The information learned from this study may help researchers better understand whether berobenatide could be a treatment option for adults living with overweight or obesity.
Conditions
- Obesity
- Overweight
Interventions
BerobenatideDrug
Solution for injection
PlaceboOther
Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Body Weight at Week 48Time frame: Baseline to Week 48
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University General Hospital
Tianjin, China · Recruiting
The Second People's Hospital of Hefei
Hefei, Anhui, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Pinggu Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing People's Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Huizhou Central People's Hospital
Huizhou, Guangdong, China · Recruiting
Harrison International Peace Hospital
Hengshui, Hebei, China · Recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
The Fourth Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Recruiting
Luoyang First People's Hospital
Luoyang, Henan, China · Recruiting
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang, Henan, China · Recruiting
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Shiyan Taihe Hospital
Shiyan, Hubei, China · Not yet recruiting
Wuhan Third Hospital
Wuhan, Hubei, China · Recruiting
Changzhou Second People's Hospital
Changzhou, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Nanjing First Hospital
Nanjing, Jiangsu, China · Recruiting
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China · Recruiting
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China · Recruiting
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China · Recruiting
Pingxiang People's Hospital
Pingxiang, Jiangxi, China · Recruiting
The Second Hospital of Jilin University
Changchun, Jilin, China · Recruiting
The First Affiliated Hospital of Xi'an Medical University
Xi'an, Shaanxi, China · Recruiting
Jinan Central Hospital
Jinan, Shandong, China · Recruiting
Zhongshan Hospital,Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
The Fifth People's Hospital of Shanghai
Shanghai, Shanghai Municipality, China · Recruiting
Pudong New Area People's Hospital Shanghai
Shanghai, Shanghai Municipality, China · Recruiting
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Huzhou Central Hospital
Huzhou, Zhejiang, China · Recruiting
The first affiliated hospital of Ningbo university
Ningbo, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.